Compare NXTS & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXTS | CELZ |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | Israel | United States |
| Employees | 9 | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.1M |
| IPO Year | N/A | 2008 |
| Metric | NXTS | CELZ |
|---|---|---|
| Price | $2.07 | $0.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 65.0K | ★ 245.2K |
| Earning Date | 05-16-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $0.66 |
| 52 Week High | $23.80 | $6.25 |
| Indicator | NXTS | CELZ |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 27.76 |
| Support Level | $0.55 | N/A |
| Resistance Level | $5.31 | $0.93 |
| Average True Range (ATR) | 0.26 | 0.07 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 34.49 | 7.13 |
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.